To the best of our knowledge, this is the first comprehensive retrospective study analyzing differences between PD-L1 inhibitors combined with chemotherapy and chemotherapy alone on multiple survival indicators in patients with ES-SCLC. This evidence concerns the gene CD274 and small cell lung carcinoma.